TN HB2075

Creates the "Helping Open Pathways to Effective (HOPE) Treatment Act" establishing a framework for ibogaine drug development clinical trials in Tennessee to seek FDA approval for treating opioid use disorder, PTSD, traumatic brain injury, depression, and other mental health conditions.

Requires research cohorts consisting of a drug developer, research institution, and hospital to submit proposals to the Department of Mental Health and Substance Abuse Services, with state funding contingent on receiving matching funds from non-state sources.

Allocates at least 5% of revenue from intellectual property and commercial rights arising from the clinical trials to the state, with at least 50% of that revenue deposited into a newly created Tennessee Mental Health Innovation Fund.

Mandates physician supervision for ibogaine administration at hospitals or licensed healthcare facilities, and requires the department to begin accepting cohort proposals no later than September 1, 2026.

Takes effect July 1, 2026, and applies only if ibogaine receives FDA approval to treat a medical condition.